A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes

Eli Lilly and Company25 enrolled

Overview

This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise using different approaches on basal rate reduction and following a test meal compared to insulin lispro (Humalog). The study may last up to approximately 10 weeks and may include up to 7 visits.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Diabetes Mellitus, Type 1

Interventions

Lyumjev with 50% basal rate reductionDRUG

Administered SC.

Humalog with 50% basal rate reductionDRUG

Administered SC.

Humalog with 100% basal rate reductionDRUG

Administered SC.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female participants with type 1 diabetes * Body mass index (BMI) between 18.5 and 29.0 kilograms per square meter (kg/m²), inclusive * Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%) * Using CSII and stable insulin regimen for at least 6 months prior to inclusion into the trial * Able to undergo at least 1 hour of moderate-intensity exercise Exclusion Criteria: * Are currently participating or recently participated in a clinical trial or any other type of medical research judged to be incompatible with this study * Have a blood loss of more than 500 milliliters (mL) within the last month * Have known allergies to insulin lispro, related compounds or any components of the study drug formulation * Have previously participated or withdrawn from this study * Have or used to have health problems or medical test results that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study * Participants who have an abnormal blood pressure and/or pulse rate * Participants with clinically significant cardiac or pulmonary disease

Locations (1)

LMC Clinical Research Inc. (Bayview)

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Pharmacodynamics (PD): Change in Plasma Glucose (PG) From the Start to the End of Exercise

Changes in PG from the start (0 minute) to end of exercise (60 minutes) were analyzed using a mixed-effect model. The model included treatment (Lyumjev with 50% basal reduction, Lyumjev with 100% basal reduction, Humalog with 50% basal reduction, and Humalog with 100% basal reduction), sequence, period, timepoint, treatment-by-timepoint interaction as fixed effects, and participant-within-sequence as a random effect.

Time frame: Start (0 minute) to end of exercise (60 minutes)

Secondary Outcomes

Pharmacodynamics (PD): Change From Baseline in Area Under the Concentration Versus Time Curve From Time 0 to 4 Hours [AUC(0-4)] of Postprandial Plasma Glucose (PPG) Post Mixed-Meal Tolerance Test (MMTT)

The outcome measure was analyzed using a mixed-effect model. The model included treatment (Lyumjev with 50% basal reduction, Lyumjev with 100% basal reduction, Humalog with 50% basal reduction, and Humalog with 100% basal reduction), sequence, and period as fixed effects, and participant-within-sequence will be included as a random effect.

Time frame: Baseline (0-hour time point prior of the MMTT), 4 hour post-meal MMTT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.